Insider Transactions in Q1 2024 at Atea Pharmaceuticals, Inc. (AVIR)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 01
2024
|
Jean Pierre Sommadossi President, CEO, and Chairman |
SELL
Open market or private sale
|
Direct |
56,910
-32.81%
|
$170,730
$3.85 P/Share
|
|
Feb 01
2024
|
Andrea Corcoran |
SELL
Open market or private sale
|
Direct |
15,843
-2.31%
|
$47,529
$3.84 P/Share
|
|
Feb 01
2024
|
Janet Mj Hammond Chief Development Officer |
SELL
Open market or private sale
|
Direct |
14,029
-28.4%
|
$42,087
$3.84 P/Share
|
|
Feb 01
2024
|
John Vavricka Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
11,819
-35.46%
|
$35,457
$3.84 P/Share
|
|
Feb 01
2024
|
Wayne Foster EVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
12,477
-37.43%
|
$37,431
$3.84 P/Share
|
|
Feb 01
2024
|
Maria Arantxa Horga Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,870
-38.21%
|
$47,610
$3.84 P/Share
|
|
Jan 31
2024
|
Jean Pierre Sommadossi President, CEO, and Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
173,467
+50.0%
|
-
|
|
Jan 31
2024
|
Andrea Corcoran |
BUY
Exercise of conversion of derivative security
|
Direct |
44,367
+6.07%
|
-
|
|
Jan 31
2024
|
Janet Mj Hammond Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
46,800
+48.65%
|
-
|
|
Jan 31
2024
|
John Vavricka Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,334
+50.0%
|
-
|
|
Jan 31
2024
|
Wayne Foster EVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,334
+50.0%
|
-
|
|
Jan 31
2024
|
Maria Arantxa Horga Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
41,534
+50.0%
|
-
|